ADA 2026 panel puts lean mass loss at the center of GLP-1 obesity treatment

Data presented at the American Diabetes Association 2026 Scientific Sessions put lean mass at the center of how clinicians think about GLP-1 obesity drugs. As a rule of thumb, about 25% of total weight lost through any intervention — diet, medication or surgery — comes from lean body mass, and with newer, higher-dose GLP-1 compounds that share can climb to 40% or more, said Ian Neeland, MD, director of cardiovascular prevention at University Hospitals Harrington Heart & Vascular Institute ^[2].

The picture is not simple. Neeland noted that tirzepatide, the molecule in Mounjaro and Zepbound, has shown dose-dependent reductions in muscle fat infiltration on MRI even as total lean mass declines ^[2].

Higher doses also mean more total weight lost, so the same fraction translates into a larger absolute amount of lean mass. In the STEP UP trial, semaglutide 7.2 mg produced mean weight loss of 20.7% compared with 17.5% at the standard 2.4-mg dose ^[2]. In REDEFINE 1, cagrilintide given with semaglutide produced 22.7% mean weight loss, with 40% of patients losing more than 25% of their body weight ^[2]. Oral semaglutide 25 mg produced mean weight loss of 13.6% to 16.6% in OASIS 4, and orforglipron produced 7.5% to 11.2% across doses ^[2].

The metabolic stakes are measurable. "Each kilogram of muscle mass loss actually reduces resting energy expenditure by 13 kilocalories," Neeland said, "compared with fat mass, which contributes 4 kilocalories" ^[2].

Exercise and protein remain the main tools studied for preserving muscle. In the S-LITE trial, pairing liraglutide with supervised resistance and aerobic training produced greater weight loss and allowed patients to gain lean mass, an outcome not seen with medication alone ^[2]. Neeland cited evidence supporting 1.2 to 1.6 grams of protein per kilogram of body weight per day, with diminishing returns above that range ^[2]. A separate 2025 obesity nutrition consensus report cited by dietitian Patti Urbanski set protein at 1.5 g/kg/day, fiber at 25 to 30 grams daily for women and 30 to 35 grams for men, fat at 25 to 60 grams daily on a lower-calorie diet, and at least 2 liters of water a day; involving registered dietitians was tied to reducing GLP-1 discontinuation by as much as 5 to 10% in trials ^[2].

Drug approaches are being tested. In the phase 2 BELIEVE trial, combining semaglutide with the myostatin inhibitor bimagrumab reduced the lean-mass share of total weight loss from roughly 21% to about 7% ^[2]. Neeland said functional outcomes remain thin. "I have not seen great large-scale trials looking at function of muscle," he said, adding that how to measure muscle function in clinic "is also not really clear" ^[2].

Why it matters for patients

The number on a scale does not show what was lost. The fraction coming from lean mass appears broadly similar across diet, medication and surgery, but because GLP-1 drugs can produce more total loss, the absolute amount of lean mass lost can be larger ^[2]. Neeland framed muscle preservation as central to long-term metabolic health and weight maintenance, not just appearance ^[2].

Joint pain data show how total weight loss and function can diverge. In the STEP 9 trial, semaglutide 2.4 mg in patients with knee osteoarthritis and a mean BMI of 40.3 produced a 13.7% mean weight change and a 41.7-point reduction on a knee pain index, compared with 27.5 points in a structured-care group, with significantly less use of pain medications including opioids ^[2]. In TRIUMPH 4, tirzepatide produced roughly 23% weight loss and similar pain reductions, raising the possibility that beyond about 10% weight loss, further loss does not add proportionally more joint benefit, said Sean Wharton, MD, PharmD ^[2]. "We need to leave the door open for biological metabolic effects on top of the actual weight," Wharton said ^[2].

No head-to-head comparison of lean mass loss across different GLP-1 drugs has been reported, so patients and clinicians do not have data showing whether one drug spares muscle better than another.

What happens next

Large trials that measure how muscles actually work, rather than only how much mass is lost, have not been reported, and there is no established way to measure muscle function in routine clinic visits ^[2]. Wharton called for MRI data, synovial biopsies and biomarker analysis in future osteoarthritis trials to separate weight effects from other metabolic effects ^[2].